Oxygen-rich chemotherapy via modified Abraxane to inhibit the growth and metastasis of triple-negative breast cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Biomaterials science"
DOI: 10.1039/c8bm00753e
Abstract: Abraxane® (Abx), an FDA approved albumin-bound paclitaxel nano-formulation, is one of the most common chemical drugs for the treatment of metastatic triple-negative breast cancer (mTNBC). However, acquired resistance and metastasis are critical factors that limit… read more here.
Keywords: chemotherapy; metastasis; abraxane; resistance ... See more keywords
Synergistic effect of Abraxane that combines human IL15 fused with an albumin‐binding domain on murine models of pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.17220
Abstract: Nab‐paclitaxel (Abraxane), which is a nanoparticle form of albumin‐bound paclitaxel, is one of the standard chemotherapies for pancreatic ductal adenocarcinoma (PDAC). This study determined the effect of Abraxane in combination with a fusion protein, hIL15‐ABD,… read more here.
Keywords: effect; ductal adenocarcinoma; abraxane; group ... See more keywords
Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Nanomedicine"
DOI: 10.2147/ijn.s490400
Abstract: Purpose Abraxane (nanoparticle albumin-bound paclitaxel) is a chemotherapeutic employed commonly for the management of various cancers including breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. Although it has clinically beneficial properties, Abraxane is accompanied… read more here.
Keywords: faers database; adverse events; unveiling hidden; abraxane ... See more keywords